David S. Pisetsky

Dr. David S. Pisetsky

Medicine and Immunology, Duke University Medical Center, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in Nature Reviews Nephrology
Verified
Journal Article
Open access
PDF file
DPDavid S. Pisetsky
David S. Pisetsky
Autoimmune diseases are a diverse group of conditions characterized by aberrant B cell and T cell reactivity to normal constituents of the host. These diseases occur widely and affect individuals of all ages, especially women. Among these diseases, the most prominent immunological manifestation is the production of autoantibodies, which provide valuable biomarkers for diagnosis, classification and disease activity. Although T cells have a key role in pathogenesis, they are technically more difficult to assay. In general, autoimmune disease results from an interplay between a genetic predisposition and environmental factors. Genetic predisposition to autoimmunity is complex and can involve multiple genes that regulate the function of immune cell populations. Less frequently, autoimmunity can result from single-gene mutations that affect key regulatory pathways. Infection seems to be a common trigger for autoimmune disease, although the microbiota can also influence pathogenesis. As shown in seminal studies, patients may express autoantibodies many years before the appearance of clinical or laboratory signs of disease — a period called pre-clinical autoimmunity. Monitoring autoantibody expression in at-risk populations may therefore enable early detection and the initiation of therapy to prevent or attenuate tissue damage. Autoimmunity may not be static, however, and remission can be achieved by some patients treated with current agents.

3 September 2020 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
DPDavid S. Pisetsky
David S. Pisetsky
PLPeter E Lipsky
Peter E Lipsky

1 December 2019 in Rheumatology
Verified
Journal Article
Open access
PDF file
SWSophia C Weinmann
Sophia C Weinmann
DPDavid S. Pisetsky
David S. Pisetsky
Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate autoreactivity, immune checkpoint inhibitor therapy is complicated by side effects known as immune-related adverse events (irAEs). The aim of this article is to review the mechanisms of these events. irAEs can involve different tissues and include arthritis and other rheumatic manifestations. The frequency of irAEs is related to the checkpoint inhibited, with the combination of agents more toxic. Because of their severity, irAEs can limit therapy and require immunosuppressive treatment. The mechanisms leading to irAEs are likely similar to those promoting anti-tumour responses and involve expansion of the T cell repertoire; furthermore, immune checkpoint inhibitors can affect B cell responses and induce autoantibody production. Better understanding of the mechanisms of irAEs will be important to improve patient outcome as well as quality of life during treatment.

1 May 2016 in Clinical Therapeutics
Verified
Journal Article
Closed access
MMMelinda Magna
Melinda Magna
DPDavid S. Pisetsky
David S. Pisetsky

23 April 2019 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
DPDavid S. Pisetsky
David S. Pisetsky
MCMegan E. B. Clowse
Megan E. B. Clowse
LCLisa G. Criscione‐Schreiber
Lisa G. Criscione‐Schreiber
JRJennifer L. Rogers
Jennifer L. Rogers

1 December 2019 in Autoimmunity Reviews
Verified
Journal Article
Closed access
DPDavid S. Pisetsky
David S. Pisetsky
XBXavier Bossuyt
Xavier Bossuyt
PMPier Luigi Meroni
Pier Luigi Meroni